Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study

MLA

Rong Deng, et al. “Population Pharmacokinetics and Exposure–response Analyses of Polatuzumab Vedotin in Patients with Previously Untreated DLBCL from the POLARIX Study.” CPT: Pharmacometrics & Systems Pharmacology, vol. 13, no. 6, June 2024, pp. 1055–66. EBSCOhost, https://doi.org/10.1002/psp4.13141.

APA

Rong Deng, Leonid Gibiansky, Tong Lu, Christopher R. Flowers, Laurie H. Sehn, Qi Liu, Priya Agarwal, Michael Z. Liao, Randall Dere, Calvin Lee, Gabriel Man, Jamie Hirata, Chunze Li, & Dale Miles. (2024). Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study. CPT: Pharmacometrics & Systems Pharmacology, 13(6), 1055–1066. https://doi.org/10.1002/psp4.13141

Chicago

Rong Deng, Leonid Gibiansky, Tong Lu, Christopher R. Flowers, Laurie H. Sehn, Qi Liu, Priya Agarwal, et al. 2024. “Population Pharmacokinetics and Exposure–response Analyses of Polatuzumab Vedotin in Patients with Previously Untreated DLBCL from the POLARIX Study.” CPT: Pharmacometrics & Systems Pharmacology 13 (6): 1055–66. doi:10.1002/psp4.13141.